クローン病の患者における母と胎児のアウトカム:集団ベースのコホート研究
Geneviève Lamarche1, Ethan Bendayan1, Haim Arie Abenhaim2,3
1Faculty of Medicine, McGill University, Montreal, Quebec, Canada.
Journal of perinatal medicine
|February 16, 2026
まとめ
母性クローン病は,妊娠前出血症,早産,先天性異常など,母親と新生児のリスクを大幅に高めます. 妊娠中の綿密なモニタリングは,より良い結果のために非常に重要です.
科学分野:
- 胃腸内科 胃腸内科
- 産科は産婦人科です.
- ペリナトロジー (Perinatology) とは
- 公衆衛生は公衆衛生である.
背景:
- クローン病の罹患率は,特に生殖年齢の女性の間で増加しています.
- クローン病が妊娠に与える影響を理解することは,母と新生児のケアに不可欠です.
研究 の 目的:
- 母性クローン病と母性および新生児における有害なアウトカムとの関連性を評価する.
- クローン病の妊婦が直面する特定のリスクを特定する.
主な方法:
- ヘルスケア・コスト・アンド・ユーティライゼーション・プロジェクト-国立入院患者サンプル (2016-2021) を利用した遡及的なコホート研究.
- 病気の国際分類,第10版 (ICD-10) のコード (K50) を用いてクローン病の妊娠の特定.
- マルチ変数ロジスティック回帰分析は,母親の特徴に調整されています.
主要な成果:
- 母性クローン病は1万人に13.1人に発生し,増加傾向にあります.
- 母親のリスクの増加には,妊娠前出血症,膜炎,胎盤剥離,器用/帝王切開による出産,産後出血,セプシス,静脈性血栓塞栓性イベントなどが含まれています.
- 新生児のリスクには,早産,先天性異常,子宮内成長制限が含まれています.
結論:
- クローン病の患者の妊娠は,不良な母体および新生児合併症のより高い発生率と関連しています.
- リスクを軽減するために,クローン病の妊婦の患者に強化された監視と管理が推奨されています.
関連する概念動画
01:30Inflammatory Bowel Disease II: Crohn's Disease
1.3K
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
1.3K
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
915
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
915
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
536
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
536
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
561
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
561
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
600
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
600
01:29Inflammatory Bowel Disease IV: Pharmacological Management
795
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
795